| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | NEIL3肽及包含它的疫苗 | CN201080012575.5 | 2010-03-15 | CN102356155B | 2016-02-24 | 角田卓也; 大泽龙司; 吉村祥子; 渡边朝久; 中村佑辅; 古川洋一 |
| 本发明提供了分离的自SEQ ID NO：45衍生的肽或片段，其结合HLA抗原和诱导细胞毒性T淋巴细胞(CTL)。这样的肽可包括上文所述氨基酸序列中替代、删除或添加一个、两个、或数个氨基酸而得到的序列。本发明还提供了包含这些肽的药物组合物。本发明的肽可用于诊断或治疗癌症。 | ||||||
| 2 | NEIL3肽及包含它的疫苗 | CN201080012575.5 | 2010-03-15 | CN102356155A | 2012-02-15 | 角田卓也; 大泽龙司; 吉村祥子; 渡边朝久; 中村佑辅; 古川洋一 |
| 本发明提供了分离的自SEQ ID NO：45衍生的肽或片段，其结合HLA抗原和诱导细胞毒性T淋巴细胞(CTL)。这样的肽可包括上文所述氨基酸序列中替代、删除或添加一个、两个、或数个氨基酸而得到的序列。本发明还提供了包含这些肽的药物组合物。本发明的肽可用于诊断或治疗癌症。 | ||||||
| 3 | PHARMACEUTICAL COMPOSITION FOR INHIBITION OF CANCER CELL METASTASIS INCLUDING siRNA FOR RIBOSOMAL PROTEIN S3 | US15629369 | 2017-06-21 | US20180346915A1 | 2018-12-06 | Joon KIM; Hag Dong KIM; YongJoong KIM |
| The present invention relates to a pharmaceutical composition for inhibiting cancer cell metastasis, the pharmaceutical composition including at least one of: (1) si-rpS3/203 binding to a 203rd base sequence of rpS3 mRNA; (2) si-rpS3/635 binding to a base sequence corresponding to a position 635 of the rpS3 mRNA; (3) si-rpS3/747 binding to a base sequence corresponding to a position 747 of the rpS3 mRNA; and (4) si-rpS3/766 binding to a base sequence corresponding to a position 766 of the rpS3 mRNA. | ||||||
| 4 | Genetic signature of vulnerability to inhibitors of base excision repair (BER) in cancer | US14890685 | 2014-05-21 | US09637798B2 | 2017-05-02 | Shwetal V. Mehta; Michael E. Berens; Harshil Dineshkumar Dhruv |
| The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG. | ||||||
| 5 | Compositions Comprising A Sirt6 Activator As A Component Of A Yeast Ferment Extract And A DNA Repair Enzyme | US15365109 | 2016-11-30 | US20170071845A1 | 2017-03-16 | Nadine Pernodet; Kelly Dong; Edward Pelle |
| Compositions of the invention comprise 8-oxoguanine glycosylase (OGG1) and SIRT6 activating peptide G-A-G-V-S-A-E-NH2. Compositions of the invention exhibit anti-aging effects by promoting the repair of skin cell DNA and/or by protecting skin cell DNA from UV damage. | ||||||
| 6 | COMPOUNDS AND METHODS FOR INHIBITION OF AP ENDONUCLEASE-1/REDOX FACTOR-1 (HAPE1) ACTIVITY | US14374516 | 2013-01-29 | US20140371259A1 | 2014-12-18 | Barry I. Gold; Xiangqun Xie; Ajay Srinivasan; LiRong Wang |
| A method for treating a neoplasm in a subject, comprising co-administering to the subject a therapeutically effective amount of an anticancer agent and a substituted 6,7-methylenedioxy-4-amino-quinoline, or a pharmaceutically acceptable salt or ester thereof. | ||||||
| 7 | DNA repair polypeptides and methods of use | US09864866 | 2001-05-23 | US20020127656A1 | 2002-09-12 | R. Stephen Lloyd; Amanda K. McCullough; Khoa Nguyen |
| The present invention provides polypeptides having pyrimidine glycosylase activity, preferably, pyrimidine glycosylase/AP lyase activity. The polypeptides include a targeting sequence, preferably an exogenous target sequence. The invention includes polynucleotides that include a coding sequence encoding the polypeptides of the present invention. Also provided by the invention are methods of using the polypeptides. | ||||||
| 8 | Sirt6活性化剤及びDNA修復酵素を含有する組成物 | JP2017530267 | 2015-11-23 | JP6391837B2 | 2018-09-19 | パーノデット,ナディーン; ドン,ケリー; ペッレ,エドワード |
| 9 | NEIL3ペプチドおよびそれを含むワクチン | JP2015106037 | 2015-05-26 | JP2015227334A | 2015-12-17 | 角田 卓也; 大沢 龍司; 吉村 祥子; 渡辺 朝久; 中村 祐輔; 古川 洋一 |
| 【課題】HLA抗原に結合し、かつ細胞傷害性Tリンパ球(CTL)を誘導する、単離されたペプチドまたは断片の提供。 【解決手段】HLA抗原に結合し、かつ細胞傷害性Tリンパ球(CTL)誘導能を有する、単離されたペプチドであって、特定のアミノ酸配列またはその免疫学的活性断片からなる、単離されたペプチド。本ペプチドは、NEIL3(NeiエンドヌクレアーゼVIII様3)またはその免疫学的活性断片からなり、HLA抗原に結合する1個、2個、または数個のアミノ酸配列の置換、欠失、または付加を伴う上記のアミノ酸配列を含み得る。 【選択図】なし |
||||||
| 10 | NEIL3ペプチドおよびそれを含むワクチン | JP2017047970 | 2017-03-14 | JP2017132786A | 2017-08-03 | 角田 卓也; 大沢 龍司; 吉村 祥子; 渡辺 朝久; 中村 祐輔; 古川 洋一 |
| 【課題】HLA抗原に結合し、かつ細胞傷害性Tリンパ球(CTL)を誘導する、単離されたペプチドまたは断片の提供。 【解決手段】HLA抗原に結合し、かつ細胞傷害性Tリンパ球(CTL)誘導能を有する、単離されたペプチドであって、特定のアミノ酸配列またはその免疫学的活性断片からなる、単離されたペプチド。本ペプチドは、NEIL3(NeiエンドヌクレアーゼVIII様3)またはその免疫学的活性断片からなり、HLA抗原に結合する1個、2個、または数個のアミノ酸配列の置換、欠失、または付加を伴う上記のアミノ酸配列を含み得る。 【選択図】なし |
||||||
| 11 | NEIL3ペプチドおよびそれを含むワクチン | JP2011539822 | 2010-03-15 | JP5799394B2 | 2015-10-28 | 角田 卓也; 大沢 龍司; 吉村 祥子; 渡辺 朝久; 中村 祐輔; 古川 洋一 |
| 12 | Ｓｉｒｔ６活性化剤及びＤＮＡ修復酵素を含有する組成物 | JP2017530267 | 2015-11-23 | JP2017538700A | 2017-12-28 | パーノデット，ナディーン; ドン，ケリー; ペッレ，エドワード |
| 本発明の組成物は8-オキソグアニングリコシラーゼ(OGG1)及びSIRT6活性化ペプチドG-A-G-V-S-A-E-NH2を含有する。本発明の組成物は、皮膚細胞DNAの修復を促進すること、及び/又はUV損傷から皮膚細胞DNAを保護することによって抗老化作用を発揮する。【選択図】図2 | ||||||
| 13 | Neil3 peptides and vaccines containing it | JP2011539822 | 2010-03-15 | JP2012520659A | 2012-09-10 | 祐輔 中村; 洋一 古川; 祥子 吉村; 龍司 大沢; 朝久 渡辺; 卓也 角田 |
| 本発明は、ＨＬＡ抗原に結合し、かつ細胞傷害性Ｔリンパ球（ＣＴＬ）を誘導する、ＳＥＱ ＩＤ ＮＯ：４５由来の単離されたペプチドまたは断片を提供する。 本ペプチドは、１個、２個、または数個のアミノ酸配列の置換、欠失、または付加を伴う上記のアミノ酸配列を含み得る。 本発明はまた、これらのペプチドを含む薬学的組成物も提供する。 本発明のペプチドは、がんを診断または治療するために用いることができる。 | ||||||
| 14 | NEIL3 PEPTIDES AND VACCINES INCLUDING THE SAME | EP10753267.3 | 2010-03-15 | EP2408913B1 | 2016-12-14 | TSUNODA, Takuya; OHSAWA, Ryuji; YOSHIMURA, Sachiko; WATANABE, Tomohisa; NAKAMURA, Yusuke; FURUKAWA, Yoichi |
| The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer. | ||||||
| 15 | NEIL3 PEPTIDES AND VACCINES INCLUDING THE SAME | EP10753267 | 2010-03-15 | EP2408913A4 | 2012-11-14 | TSUNODA TAKUYA; OHSAWA RYUJI; YOSHIMURA SACHIKO; WATANABE TOMOHISA; NAKAMURA YUSUKE; FURUKAWA YOICHI |
| The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer. | ||||||
| 16 | NEIL3 PEPTIDES AND VACCINES INCLUDING THE SAME | EP10753267.3 | 2010-03-15 | EP2408913A1 | 2012-01-25 | TSUNODA, Takuya; OHSAWA, Ryuji; YOSHIMURA, Sachiko; WATANABE, Tomohisa; NAKAMURA, Yusuke; FURUKAWA, Yoichi |
| The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer. | ||||||
| 17 | NEIL3 PEPTIDES AND VACCINES INCLUDING THE SAME | US15928582 | 2018-03-22 | US20180222954A1 | 2018-08-09 | Takuya Tsunoda; Ryuji Ohsawa; Sachiko Yoshimura; Tomohisa Watanabe; Yusuke Nakamura; Yoichi Furukawa |
| The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer. | ||||||
| 18 | NEIL3 peptides and vaccines including the same | US15228785 | 2016-08-04 | US09975935B2 | 2018-05-22 | Takuya Tsunoda; Ryuji Ohsawa; Sachiko Yoshimura; Tomohisa Watanabe; Yusuke Nakamura; Yoichi Furukawa |
| The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 45, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences. The invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for diagnosing or treating cancer. | ||||||
| 19 | GENETIC SIGNATURE OF VULNERABILITY TO INHIBITORS OF BASE EXCISION REPAIR (BER) IN CANCER | US15475344 | 2017-03-31 | US20170204472A1 | 2017-07-20 | Shwetal V. Mehta; Michael E. Berens; Harshil Dineshkumar Dhruv |
| The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG. | ||||||
| 20 | Compounds and methods for inhibition of AP endonuclease-1/redox factor-1 (HAPE1) activity | US14374516 | 2013-01-29 | US09624235B2 | 2017-04-18 | Barry I. Gold; Xiangqun Xie; Ajay Srinivasan; LiRong Wang |
| A method for treating a neoplasm in a subject, comprising co-administering to the subject a therapeutically effective amount of an anticancer agent and a substituted 6,7-methylenedioxy-4-amino-quinoline, or a pharmaceutically acceptable salt or ester thereof. | ||||||
QQ群二维码
意见反馈
意见反馈